S&P 500   4,626.31 (+1.30%)
DOW   34,819.40 (+0.97%)
QQQ   398.04 (+1.07%)
AAPL   167.63 (+1.41%)
MSFT   334.49 (+1.18%)
FB   326.68 (+0.68%)
GOOGL   2,901.40 (+2.24%)
AMZN   3,532.09 (+0.71%)
TSLA   1,151.71 (+0.61%)
NVDA   328.47 (+0.52%)
BABA   127.43 (-0.08%)
NIO   39.72 (+1.51%)
CGC   10.78 (+0.65%)
AMD   158.18 (-0.12%)
GE   96.50 (+1.59%)
MU   88.27 (+5.08%)
T   23.07 (+1.05%)
F   20.20 (+5.26%)
DIS   147.82 (+2.02%)
ACB   6.46 (+0.62%)
PFE   53.67 (-0.11%)
AMC   34.32 (+1.12%)
BA   199.54 (+0.85%)
S&P 500   4,626.31 (+1.30%)
DOW   34,819.40 (+0.97%)
QQQ   398.04 (+1.07%)
AAPL   167.63 (+1.41%)
MSFT   334.49 (+1.18%)
FB   326.68 (+0.68%)
GOOGL   2,901.40 (+2.24%)
AMZN   3,532.09 (+0.71%)
TSLA   1,151.71 (+0.61%)
NVDA   328.47 (+0.52%)
BABA   127.43 (-0.08%)
NIO   39.72 (+1.51%)
CGC   10.78 (+0.65%)
AMD   158.18 (-0.12%)
GE   96.50 (+1.59%)
MU   88.27 (+5.08%)
T   23.07 (+1.05%)
F   20.20 (+5.26%)
DIS   147.82 (+2.02%)
ACB   6.46 (+0.62%)
PFE   53.67 (-0.11%)
AMC   34.32 (+1.12%)
BA   199.54 (+0.85%)
S&P 500   4,626.31 (+1.30%)
DOW   34,819.40 (+0.97%)
QQQ   398.04 (+1.07%)
AAPL   167.63 (+1.41%)
MSFT   334.49 (+1.18%)
FB   326.68 (+0.68%)
GOOGL   2,901.40 (+2.24%)
AMZN   3,532.09 (+0.71%)
TSLA   1,151.71 (+0.61%)
NVDA   328.47 (+0.52%)
BABA   127.43 (-0.08%)
NIO   39.72 (+1.51%)
CGC   10.78 (+0.65%)
AMD   158.18 (-0.12%)
GE   96.50 (+1.59%)
MU   88.27 (+5.08%)
T   23.07 (+1.05%)
F   20.20 (+5.26%)
DIS   147.82 (+2.02%)
ACB   6.46 (+0.62%)
PFE   53.67 (-0.11%)
AMC   34.32 (+1.12%)
BA   199.54 (+0.85%)
S&P 500   4,626.31 (+1.30%)
DOW   34,819.40 (+0.97%)
QQQ   398.04 (+1.07%)
AAPL   167.63 (+1.41%)
MSFT   334.49 (+1.18%)
FB   326.68 (+0.68%)
GOOGL   2,901.40 (+2.24%)
AMZN   3,532.09 (+0.71%)
TSLA   1,151.71 (+0.61%)
NVDA   328.47 (+0.52%)
BABA   127.43 (-0.08%)
NIO   39.72 (+1.51%)
CGC   10.78 (+0.65%)
AMD   158.18 (-0.12%)
GE   96.50 (+1.59%)
MU   88.27 (+5.08%)
T   23.07 (+1.05%)
F   20.20 (+5.26%)
DIS   147.82 (+2.02%)
ACB   6.46 (+0.62%)
PFE   53.67 (-0.11%)
AMC   34.32 (+1.12%)
BA   199.54 (+0.85%)
NASDAQ:LGND

Ligand Pharmaceuticals Stock Forecast, Price & News

$163.48
+1.56 (+0.96%)
(As of 12/1/2021 10:24 AM ET)
Add
Compare
Today's Range
$162.43
$164.74
50-Day Range
$127.69
$165.85
52-Week Range
$82.25
$219.75
Volume
357 shs
Average Volume
288,596 shs
Market Capitalization
$2.73 billion
P/E Ratio
40.97
Dividend Yield
N/A
Beta
1.06
30 days | 90 days | 365 days | Advanced Chart
Receive LGND News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Ligand Pharmaceuticals logo

About Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:LGND
CUSIP
53220K50
Employees
2,018
Year Founded
N/A

Sales & Book Value

Annual Sales
$186.42 million
Cash Flow
$6.87 per share
Book Value
$44.12 per share

Profitability

Net Income
$-2.98 million
Pretax Margin
21.01%

Debt

Price-To-Earnings

Miscellaneous

Free Float
15,091,000
Market Cap
$2.73 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/02/2022

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

405th out of 1,390 stocks

Pharmaceutical Preparations Industry

186th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions

Is Ligand Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ligand Pharmaceuticals stock.
View analyst ratings for Ligand Pharmaceuticals
or view top-rated stocks.

How has Ligand Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Ligand Pharmaceuticals' stock was trading at $91.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LGND shares have increased by 78.0% and is now trading at $163.48.
View which stocks have been most impacted by COVID-19
.

When is Ligand Pharmaceuticals' next earnings date?

Ligand Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 2nd 2022.
View our earnings forecast for Ligand Pharmaceuticals
.

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) released its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.61 by $0.97. The biotechnology company had revenue of $64.84 million for the quarter, compared to analyst estimates of $60.46 million. Ligand Pharmaceuticals had a net margin of 24.87% and a trailing twelve-month return on equity of 10.18%. During the same quarter in the previous year, the business posted $0.71 earnings per share.
View Ligand Pharmaceuticals' earnings history
.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals updated its FY 2021 earnings guidance on Tuesday, November, 30th. The company provided earnings per share guidance of $5.800-$6.050 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.930. The company issued revenue guidance of $265 million-$275 million, compared to the consensus revenue estimate of $270.82 million.

What price target have analysts set for LGND?

4 Wall Street analysts have issued 12 month target prices for Ligand Pharmaceuticals' stock. Their forecasts range from $180.00 to $310.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $223.75 in the next year. This suggests a possible upside of 36.9% from the stock's current price.
View analysts' price targets for Ligand Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Ligand Pharmaceuticals' key executives?

Ligand Pharmaceuticals' management team includes the following people:
  • John L. Higgins, Chief Executive Officer & Director
  • Matthew William Foehr, President & Chief Operating Officer
  • Matthew Edward Korenberg, Chief Financial Officer & Executive VP-Finance
  • Eric Vajda, Vice President-Preclinical Research & Development
  • Charles Stuart Berkman, Secretary, Senior Vice President & General Counsel

What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?

1 employees have rated Ligand Pharmaceuticals CEO John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among Ligand Pharmaceuticals' employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (8.75%), William Blair Investment Management LLC (8.25%), Macquarie Group Ltd. (3.87%), Villere ST Denis J & Co. LLC (3.38%), Chicago Capital LLC (2.64%) and Stephens Investment Management Group LLC (2.46%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, John L Higgins, Matthew W Foehr and Todd C Davis.
View institutional ownership trends for Ligand Pharmaceuticals
.

Which major investors are selling Ligand Pharmaceuticals stock?

LGND stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., New York State Common Retirement Fund, Citigroup Inc., Granahan Investment Management Inc. MA, Voloridge Investment Management LLC, Dimensional Fund Advisors LP, Kornitzer Capital Management Inc. KS, and Villere ST Denis J & Co. LLC. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, John L Higgins, Matthew W Foehr, and Todd C Davis.
View insider buying and selling activity for Ligand Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Ligand Pharmaceuticals stock?

LGND stock was acquired by a variety of institutional investors in the last quarter, including Cardinal Capital Management LLC CT, William Blair Investment Management LLC, Nordea Investment Management AB, MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income, Principal Financial Group Inc., Macquarie Group Ltd., Stephens Investment Management Group LLC, and Public Sector Pension Investment Board.
View insider buying and selling activity for Ligand Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $163.48.

How much money does Ligand Pharmaceuticals make?

Ligand Pharmaceuticals has a market capitalization of $2.73 billion and generates $186.42 million in revenue each year. The biotechnology company earns $-2.98 million in net income (profit) each year or $3.99 on an earnings per share basis.

How many employees does Ligand Pharmaceuticals have?

Ligand Pharmaceuticals employs 2,018 workers across the globe.

What is Ligand Pharmaceuticals' official website?

The official website for Ligand Pharmaceuticals is www.ligand.com.

Where are Ligand Pharmaceuticals' headquarters?

Ligand Pharmaceuticals is headquartered at 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 550-7500, via email at [email protected], or via fax at 858-550-1826.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.